Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Statement of Solidarity after Earthquake in Morocco

On behalf of the European Hematology Association, I would like to express my deepest condolences and heartfelt support to the people of Morocco who have been affected by the recent earthquake.

Read more

EHA-ASH Translational Research Training in Hematology

TRTH 2025 call is now closed. What is Translational Research Training in Hematology?Translational Research Training in Hematology (TRTH) provides early-career researchers with a unique, year-long training and mentoring experience.

Read more

EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders in EU is €23 billion

In Europe blood disorders affect around 80 million people. The total cost of blood disorders consists of healthcare expenditure (€15. 6 billion), productivity loss due to illness and mortality (€5. 6 billion), and the costs of informal care (€1.

Read more

Rebuilding the future for hematology in Ukraine today

The Hague (Netherlands), December 5, 2022 - Nearly 8 million Ukrainians have fled their country since February 24 according to the UN Refugee Agency, while about 5 million people have moved back.

Read more